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Interaction between the MTHFR C677T polymorphism
and traumatic childhood events predicts depression
A Lok1, CLH Bockting2, MWJ Koeter1, H Snieder3, J Assies1, RJT Mocking1, CH Vinkers4, RS Kahn4, MP Boks4 and AH Schene1
Childhood trauma is associated with the onset and recurrence of major depressive disorder (MDD). The thermolabile T variant of
the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism (rs1801133) is associated with a limited (oxidative)
stress defense. Therefore, C677T MTHFR could be a potential predictor for depressive symptomatology and MDD recurrence in
the context of traumatic stress during early life. We investigated the interaction between the C677T MTHFR variant and exposure
to traumatic childhood events (TCEs) on MDD recurrence during a 5.5-year follow-up in a discovery sample of 124 patients with
recurrent MDD and, in an independent replication sample, on depressive symptomatology in 665 healthy individuals from the
general population. In the discovery sample, Cox regression analysis revealed a significant interaction between MTHFR
genotype and TCEs on MDD recurrence (P¼ 0.017). Over the 5.5-year follow-up period, median time to recurrence was 191 days
for T-allele carrying patients who experienced TCEs (Tþ and TCEþ ); 461 days for T and TCEþ patients; 773 days for Tþ
and TCE patients and 866 days for T and TCE patients. In the replication sample, a significant interaction was present
between theMTHFR genotype and TCEs on depressive symptomatology (P¼ 0.002). Our results show that the effects of TCEs on
the prospectively assessed recurrence of MDD and self-reported depressive symptoms in the general population depend on the
MTHFR genotype. In conclusion, T-allele carriers may be at an increased risk for depressive symptoms or MDD recurrence after
exposure to childhood trauma.
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Introduction
Childhood maltreatment is associated with substantial and
long-lasting cognitive and biological effects on the brain
including heightened stress sensitivity. Therefore, individuals
who have been exposed to childhood maltreatment are
predisposed to an unfavorable course of major depressive
disorder (MDD) and treatment outcome, as indicated by a
recent meta-analysis.1 However, not all individuals exposed
to traumatic stress develop a depression. Therefore, it is
important to characterize the gene–environment interplay
underlying the effects of traumatic childhood events (TCEs)
on depression outcomes.
After a first episode of MDD,B50% of patients will experi-
ence recurrences, which are responsible for considerable
disability and impairment.2–5 Burcusa and Iacono6 stated as
an explanation for recurrence in MDD that ‘individuals at high
risk for multiple episodes possess the necessary character-
istics to make them prone to recurrent depression, and such
characteristics exist even before their first episode’. The
recurrent type of MDD has a higher heritability than a single
episode of MDD.7 Furthermore, biological studies in indivi-
duals at risk for MDD, or remitted from MDD, as well as their
nondepressed family members, showed that pathophysiolo-
gical disturbances also precede the development of MDD and
remain present after remission, suggestive of stable heritable
vulnerability traits, that is, endophenotypes.8–12 However, a
direct identification of candidate genes with recurrence of
MDD has proven to be difficult, presumably as a result of
complex interactions between genes and environmental
stressors.13,14
A recently emerged pathway potentially underlying sus-
ceptibility to onset, symptomatology and recurrence of MDD is
folate-mediated one-carbon (1-C) metabolism.15,16 The 1-C-
cycle plays a central role in (1) the regulation of oxidative
stress and (2) the generation of methyl groups for methylation
of DNA, proteins, phospholipids and neurotransmitters.17,18
A crucial enzyme in this pathway is 5,10-methylenetetrahy-
drofolate reductase (MTHFR). A single-nucleotide poly-
morphism (SNP) in the MTHFR gene (C677T or rs1801133)
results in the production of a thermolabile variant of MTHFR,
which is associated with decreased methylation capacity19
and increased oxidative stress. This genetically determined
variation in 1-C cycle activity associated with increased stress
sensitivity may contribute to alterations in neurocognitive
functioning and mood regulation.20,21
Nevertheless, results of meta-analyses on data linking
polymorphisms in the MTHFR gene with MDD have been
inconsistent.22–26 From these studies it has become apparent
that the main genetic effects overall are weak in MDD,
whereas gene–environment interactions may provide stron-
ger predictors.27 Investigating genetic susceptibility to stress
is of particular relevance in the context of MDD as stress is
considered one of the main pathogenic factors involved in
depressive symptomatology and MDD recurrence: TCEs,
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recent life events, daily hassles and stress related to previous
depressive episodes all pose increased risks for MDD and its
recurrences.1,28–32 Especially during early life, traumatic
stress may result in lifelong programming, potentially through
methylation-mediated alterations in expression of genes
implicated in MDD.27,33–39 As mentioned above, the thermo-
labile T variant of the MTHFR C677T polymorphism is
associated with increased vulnerability to oxidative stress
and a decreased DNA methylation capacity. Therefore,
carriers of the MTHFR C677T variant may be particularly
vulnerable to long-lasting effects of childhood traumatic stress
on depressive symptomatology and MDD.
To study this proposed relation, we investigated the
possible gene environment interaction between TCEs and
the MTHFR genotype as a potential predictor for depressive
symptoms and recurrence in patients with a high risk of
recurrence of depression over a 5.5-year follow-up period. We
hypothesized that recurrently depressed patients carrying the
T-allele would have a shorter time to MDD recurrence after
exposure to TCEs, whereas this association would not be
present in T-allele carriers without exposure to TCEs.
Because the effects of the MTHFR genotype may
not only be limited to MDD but also be present in the
general population, we examined this gene–environment
interaction in an independent population-based sample for
replication.
Materials and methods
Study participants. The current study was part of the
DELTA study, a randomized clinical trial, investigating the
effect of cognitive therapy on recurrence in 172 euthymic
patients.40,41 In the DELTA study, we sampled a group of
patients with recurrent MDD. We considered these patients
to suffer from a more biologically pronounced and endogen-
ously determined subtype of MDD with a relatively high
recurrence rate.12 Inclusion criteria of the original trial were:
Z2 previous MDD episodes in the past 5 years, as defined
by the Structured Clinical Interview for DSM-IV disorders
(SCID);42 in remission 410 weeks and o2 years ago, as
defined as a score of o10 on the 17-item Hamilton
Depression Rating Scale (HDRS17)
43; and 18–65 years old.
Exclusion criteria were: (a history of) bipolar spectrum
disorder or any psychotic disorder, organic brain damage,
alcohol and/or drug abuse and/or dependency or predomi-
nant anxiety disorder, all assessed by the SCID. The
background, methodology and procedure of the DELTA
study have been described in more detail previously.40 At 2
years after baseline, we asked the patients to provide DNA
for the current study. After complete description of the study
to the subjects, written informed consent was obtained
before enrolment. The study was approved by the ethics
committee of the Academic Medical Center of the University
of Amsterdam (MEC 02/048).
CannabisQuest cohort. Participants in the discovery sam-
ple were recruited using a project website launched in 2006
targeted at Dutch young adults and adolescents from age 18
to 25 years (www.cannabisquest.nl).44 Strategies to gener-
ate traffic on the project website included collaboration with
over a hundred colleges, universities and youth centers, as
well as the use of online commercial advertisement products
(that is, banners and text links).44 The chance to win an
Apple iPod or a Nintendo Wii was used as an incentive.
Double entries were prevented by exclusion of subjects with
an identical e-mail address, surname and date of birth.
Anonymous submission of data was not possible. The online
assessment included verification questions to protect against
random answers, and participants failing to correctly com-
plete the verification questions were subsequently excluded.
From the online data (N¼ 17 698), 1259 participants were
included for subsequent genetic assessment in two waves.
First, in order to increase power for gene environment
interactions,45 in the context of cannabis and psychosis, we
prioritized a sample of 719 participants who belonged to the
top or bottom quintile of total scores of psychotic experiences
as measured by the Community Assessment of Psychic
Experiences (CAPE) score who were either cannabis naive
(that is, a lifetime cannabis exposure frequency ofo6 times)
or were heavy cannabis users (that is, current expenditure for
personal cannabis use exceeded 3h weekly). Second, an
unselected sample of 540 individuals was included. As
ascertained with the validated Dutch version of either the
SCID42 or the MINI International Neuropsychiatric Inter-
view,46 healthy controls had no history of any psychotic
disorder. For 84 participants, no interview data were
available, and for these cases the presence of a psychotic
disorder was excluded by the absence of antipsychotic drug
use or a history of psychiatric treatment. The possible
concomitant use of recreational drugs was assessed with the
substance abuse module of the Composite International
Diagnostic Interview.47 Of the 1259 participants who com-
pleted comprehensive assessments and provided blood
samples for genetic testing, complete data were available
for 665 subjects because of a later implementation of the
Childhood Trauma Questionnaire (CTQ)48 assessment in the
study. All participants provided a urine sample to screen for
the presence of recreational drugs in order to verify recent
self-reported cannabis use. The study was approved by the
ethical review board of the University Medical Center Utrecht
and all participants gave written informed consent.
Measurements
Depression
Discovery sample. Using SCID-I, current and past depres-
sive episodes were assessed at baseline, and at 5 follow-up
measurements at 3, 12, 24, 36 and 66 months after baseline.
With these follow-up assessments, we diagnosed relapses
(o6 months after a previous major depressive episode) or
recurrences during follow-up, both further addressed as
‘recurrence’ for clarity reasons. The trained SCID evaluators
were blind to treatment condition and subjects were
instructed not to reveal their treatment condition to the
interviewers (psychologist/research assistants). All inter-
views were audio taped. Two independent experienced
psychiatrists, also blinded to treatment condition, evaluated
all occasions of participants meeting the DSM-IV criteria for
MDD. In cases of disagreement, we used the ratings of the
psychiatrists. The k-value for inter-rater agreement between
the interviewers and psychiatrist on categorization of a
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relapse/recurrence or no relapse/recurrence was 0.96,
indicating high agreement.40
Replication sample. In the replication sample, the Beck
Depression Inventory (BDI) was used to assess depressive
symptoms. This validated 21-item self-report questionnaire
measures current depressive symptoms during the last
week. Each question has four possible answer choices rang-
ing in intensity (0–3), resulting in a total BDI score ranging
from 0 to 63.
Traumatic childhood events
Discovery sample. We defined TCEs as having experienced
one of the following traumatic events before age 16: parental
loss, sustained alcohol and/or drug abuse by caregiver,
victim of a serious crime, victim of a serious accident and
victim of sexual and/or physical abuse. We selected
traumatic stress variables and stressors occurring to the self
within this age period using the 7 items from the Negative Life
Events Questionnaire that indicate traumatic events: items 5
and 8–13.49,50 This questionnaire proved to have a good
predictive validity, as the number of negative life events
predicted MDD symptom severity. We dichotomized the
absence or presence of experienced TCEs.
Replication sample. In the replication sample, childhood
maltreatment was assessed using the 25-item version of the
CTQ.48 The CTQ assesses five types of self-report childhood
trauma: emotional abuse, physical abuse, sexual abuse,
emotional neglect and physical neglect. The validity of the
CTQ, including a Dutch translation, has been demonstrated in
clinical and community samples.48,51 One translated item
(I believe I was molested) was excluded as this translation
was found to be an invalid indicator of childhood sexual abuse
in a previous validation study.51 Childhood maltreatment was
used as the continuous sum score divided by the number of
completed items. One item of the CTQ was only available for a
subset of the replication sample (My family was a source of
strength and support). Additional analyses in which this item
was excluded altogether did not affect the results.
Genotyping procedures and analysis
Discovery sample. We collected 20 ml blood samples at
patients’ homes by venipuncture. DNA was isolated from
blood using a filter-based method (QIAamp DNA Mini Kit,
Qiagen, Manchester, UK). The PCR primers were designed
using Primer 3 (http://frodo.wi.mit.edu/primer3/input.htm).
The PCR primer sequence was 50-GGCAGGTTACCCCA
AAGGC-30 and 50-TGGGGTGGAGGGAGCTTATG-30, and
the PEX primer sequence was 50-GAGAAGGTGTCTLC
GGGAG-30. Genotyping was done using a matrix-assisted
laser desorption/ionization time-of-flight mass spectrometer
from Bruker Daltonics (Wormer, The Netherlands). All
samples were genotyped in duplicate to increase reliability.52
Genotyping error rate based on these duplicates was 3.7%.
Replication sample. All participants were of Dutch ancestry.
Genotype data were generated on three different array
platforms: the Illumina (San Diego, CA, USA) Human Omni
Express (N¼ 576), the Illumina Human610-Quad Beadchip
(N¼ 768) and the Illumina HumanHap550 array (N¼ 34). For
each SNP platform, quality control procedures were initially
performed separately using PLINK V1.07.53 Subjects were
excluded based on 45% missing genotypes and gender
errors. We used linkage disequilibrium-based SNP pruning to
select the most informative SNPs (R2 o0.2) only for the
subsequent quality control step. This resulted inB67k SNPs for
the sets to assess heterozygosity (Fo3 s.d.), homozygosity
(F43 s.d.) and relatedness by pairwise identity-by-descent
values (PIHAT 40.15). Data sets were merged with Hapmap
Phase 3 individuals to check ethnicity. After these quality
control procedures on subjects (excluding in total 101 indi-
viduals), quality control on SNPs was performed as follows.
All SNPs were filtered on missingness (42%) and Hardy–
Weinberg (P41e 6) before merging the three data sets. Four
duplicates and three related sample pairs were detected in
the merged data sets (according to criteria described above)
and one outlier after clustering the merged data set. From
these data, the MTHFR genotype (rs1801133) was extracted.
Cannabis use (replication sample). In the replication sample,
cannabis use was defined as current use of more than an
equivalent of 3h per week (roughly equivalent to weekly
cannabis use) during the past month or longer. The monetary
amount spent on cannabis has been reported as a valid
proxy of exposure to D9-tetrahydrocannabinol.54
Statistical analysis
Genotypes. Although significantly different enzymatic activity
and thermolability were reported, overlapping profiles for the
TT and CT genotypes have been described, with CC remaining
as a distinct genotype.55 Therefore, and for power reasons, the
MTHFR C677T polymorphism variable was dichotomized into
T-allele carriers (TT and CT combined) and non-T carriers (the
wild-type genotype CC) groups in the discovery sample. In the
replication sample, genotypes were coded 0, 1, or 2 and
modeled as a linear effect (additive genetic model) to account
for different genotype distributions because it avoids small
subgroup stratification.57 Deviation from Hardy–Weinberg
equilibrium was tested by allele counting and w2 analysis.
Discovery sample. The interaction between the MTHFR
genotype and TCEs on MDD recurrence was investigated
using Cox regression, which takes into account differences in
time at risk and censoring (no recurrence during the study
period of 5.5 years). Half the study sample was randomly
allocated to preventive cognitive therapy (CT: 8 sessions
during the first 3 months after inclusion in the DELTA study).
Preventive CT has a protective effect on recurrence that
increases with the number of previous depressive epi-
sodes.40 To test whether this intervention modified the
relation between MTHFR genotype, TCEs and recurrence,
we assessed the significance of the four-way interaction of
treatment condition by MTHFR genotype by TCEs by the
number of previous episodes. Because neither the four-way
MTHFR genotype by TCEs by treatment by previous
episodes nor the three-way MTHFR genotype by TCEs by
treatment interaction terms were significant, patients who
were or were not randomized to receive CT were pooled for
the Cox regression analyses. MTHFR, TCEs and MTHFR
TCEs were included as predictors in the model; the
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interaction term tests our hypothesis whether the effect of the
MTHFR C677T variant (T-allele carrier, non-T carrier) is
modified by TCEs (present, absent). To ensure that our
results were not influenced by initial differences in group
characteristics, we also reanalyzed the data adjusted for age,
gender and antidepressant use by incorporating these
variables as covariates in the Cox regression model. We
used PASW statistics 18.0 (IBM SPSS, 2010, Chicago, IL,
USA). We considered Po0.05 statistically significant.
Replication sample. To examine the interaction between the
MTHFR genotype and TCEs on depressive symptoms, the
total BDI score was regressed on TCEs, MTHFR genotype,
their interaction and covariates using the following model:
BDI¼ b0þ (b1*covariate)þ (b2* rs1801133)þ (b3*TCEs)þ
(b4* rs1801133*TCEs). As covariates we included cannabis
use (modeled as a dichotomous indicator), age and gender.
Analyses were performed in R (www.r-project.org).56 Con-
tinuous sum scores of the BDI and the CTQ were used.
Results
Sample characteristics. Descriptives of both samples are
depicted in Table 1.
Discovery sample. Of the 172 patients of the original trial,
137 provided DNA. Of these 35 patients, 15 (8.7%) were lost
to follow-up and the remaining patients (11.6%) did not
participate because of a diversity of reasons (for example,
being afraid of needles, ethical issues concerning genetic
study). Five patients could not be analyzed because of
MTHFR C677T genotyping failure (genotyping success
rate¼ 96.3%). Of the remaining 132 patients, 1 was non-
Caucasian, 2 were lost to follow-up and we could not obtain
TCEs data for 4 patients. All analyses pertain to the resulting
124 patients. These 124 patients were comparable to the
other 48 patients on gender, age, educational level, number
of previous episodes and age of onset of first depression, but
differed on marital status and antidepressant use. Compared
with the 48 excluded patients, the 124 remaining patients
comprised fewer singles (37% vs 54%; w2¼ 4.14, d.f.¼ 1,
P¼ 0.042), and more users of antidepressants (57% vs 35%;
w2¼ 6.61, d.f.¼ 1, P¼ 0.010).
The MTHFR C677T genotype counts and frequencies in the
patients were 60 (48.4%) for the CC variant, 49 (39.5%) for the
CT variant and 15 (12.1%) for the TT variant. No deviation from
Hardy–Weinberg Equilibrium was observed (w2¼ 1.00, d.f.¼ 1,
P¼ 0.317). T-allele carriers and non-T-allele carriers were
largely comparable on demographic and psychopathological
characteristics (Table 2), with the exception of educational
level, and body mass index. T-allele carriers comprised more
persons with medium-level education and had a higher mean
body mass index, whereas non-T-allele carriers comprised
more individuals with higher-level education.
Replication sample. Table 1 reports the distribution of
demographic characteristics, childhood maltreatment, BDI
and the MTHFR C677T genotype from individuals in the
replication sample. Characteristics in the replication sample
generalized to the full sample that includes all nongenotyped
individuals.44 Genotyping was successful in all subjects and no
departure from Hardy–Weinberg Equilibrium was detected.
Recurrence in the discovery sample. Overall, 98 patients
(79.0%) experienced relapse/recurrence at least once over
the 5.5 years. Mean time to recurrence was 750 days
(s.e.¼ 61.7 with a median of 493 days (range 20–2056
days)). The MTHFR C677T by TCE interaction predicted
time to recurrence (P¼ 0.017). This indicates that the
predictive effect of TCEs on MDD recurrence was modified
by MTHFR genotype (T-allele carriers; Table 3). This result
Table 1 Characteristics of the discovery and replication samples
Discovery sample Replication sample
Characteristics (n¼ 124) (n¼665)
Female % 74 56
Age (range) 44.5 (21–63) 20.5 (18–40)
Depression scorea 3.6 (0–9) 5.4 (0–34)
Caucasian % 100 100
MTHFR C677T genotype (rs1801133)
T/T, % 12 10
T/C, % 40 43
C/C, % 48 47
HWE (P-value) 0.32 0.94
Childhood traumab 44 1.4 (1.0–4.3)
Abbreviations: HWE, Hardy–Weinberg equilibrium; MTHFR, methylenetetra-
hydrofolate reductase.
aDiscovery sample: Hamilton depression rating scale (HDRS) total score;
replication sample: Beck Depression Inventory (BDI) total score. bDiscovery
sample: percent experienced traumatic childhood event(s) (TCE); replication
sample: total score Childhood Trauma Questionnaire (CTQ).
Table 2 Demographic and clinical characteristics of the discovery sample (D) a
T-carriers
(n¼ 64)
Non-T-carriers
(n¼ 60)
Characteristics Mean s.d. Mean s.d. P-value
Sex (M/F) 16/48 16/44 0.832
Age, year 44.0 9.8 45.1 9.7 0.534
Educational levelb 0.020
Low, % 34 32
Middle, % 39 20
High, % 27 48
Marital status (single), % 42 32 0.226
Received cognitive therapy, % 48 58 0.270
AD use, yes % 56 58 0.815
BMI 28.0 6.0 26.0 4.3 0.045
HDRS17 score 3.8 3.0 3.5 3.0 0.638
Number of previous episodes 4.5 4.7 7.0 12.0 0.138
Age of first onset, years 29.4 12.7 27.9 12.7 0.510
Psychiatric diseases first
relatives (%)
63 75 0.150
TCEs (%) 40.6 46.7 0.498
Abbreviations: AD, antidepressant, BMI, body mass index, F, female; HDRS17,
17-item Hamilton Depression Rating Scale; M, male; TCE, traumatic childhood
event.
Group comparisons were calculated using Student’s t-tests, w2 tests or Fisher’s
exact tests.
aAll data represent baseline values. bEducational level is defined as follows: low,
primary education or preparatory middle-level applied education; middle, higher
general continued education or middle-level applied education; high, prepara-
tory scientific education, higher applied education or scientific education.
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did not change after adjusting for age, gender and
antidepressant use (P¼ 0.016).
The extent of the effect modification can be seen by
comparing the risk for recurrence between the four MTHFR
C677T by TCE combination groups (Tþ and TCEþ N¼ 26;
Tþ and TCE N¼ 38; T and TCEþ N¼ 28; T and
TCE N¼ 32). We found a significantly higher hazard for the
Tþ and TCEþ groups as compared with the T and TCE
groups (hazard ratio 3.55; Wald 17.7, d.f.¼ 1, Po0.001). For
patients who experienced TCEs, the hazard for recurrence in
T-allele carriers was 2.4 times higher than in non-T-allele
carriers (P¼ 0.002; Figure 1). This corresponds to the
observed differences in median time till recurrence that were
respectively 191 days for Tþ and TCEsþ patients; 461 days
for T and TCEþ patients; 773 days for Tþ and TCE
patients and 866 days for T and TCE patients.
Depressive symptoms in the replication sample. Table 4
shows the results of the linear regression model in the
replication sample. Significant effects on depressive symp-
toms were present for childhood maltreatment (b¼ 11.08,
P¼ 5.7 10 11), gender (b¼  1.06, P¼ 0.036), cannabis
use (b¼ 1.25, P¼ 0.027) and the MTHFR genotype (b¼ 4.13,
P¼ 0.0054). Moreover, there was a significant interaction
between childhood maltreatment and the MTHFR genotype
(b¼  3.19, P¼ 0.0027). For individuals carrying the TT
genotype, childhood maltreatment resulted in increased
levels of depressive symptoms (Figure 2).
To ensure that cannabis use in the replication sample did
not influence the interaction between the MTHFR genotype
and childhood maltreatment, additional stratified analyses
were carried out in noncannabis users (N¼ 478) and cannabis
users (N¼ 187).
In both subsamples of the replication sample, the
MTHFRmaltreatment interaction was present with a similar
directionality (P¼ 0.050 and P¼ 0.056). Moreover, cannabis
use did not interact with the MTHFR genotype in the
replication sample (P¼ 0.85). Therefore, it is unlikely that
Table 3 Effect of MTHFR modified by TCE in the discovery sample
b s.e.b Wald d.f. P-value RR
MTHFR 0.081 0.284 0.080 1 0.777 0.923
TCE 0.368 0.296 1.544 1 0.214 1.445
MTHFRTCE a 0.979 0.410 5.713 1 0.017 2.663
Abbreviations: MTHFR, methylenetetrahydrofolate reductase; TCE, traumatic
childhood event; RR, relative risk.
Cox regression analysis.
MTHFR: T-allele carrying patients versus non-T-allele carrying patients, with
non-T-allele carriers as the reference category.
TCE: experienced TCE yes/no, with no TCE as the reference category.
aP¼0.016 after adjustment for age, gender and antidepressant (AD) use.
Figure 1 The effect of the gene–environment interaction between methylene-
tetrahydrofolate reductase (MTHFR) and traumatic childhood events (TCEs) on
time to recurrence in 124 euthymic patients with recurrent major depressive disorder
(MDD) over 5.5 years. Tþ TCEþ vs T TCE ¼ 3.55 (Po0.001); Tþ
TCE vs T TCE ¼ 0.92 (P¼ 0.78); and T TCE vs T TCE ¼ 1.45
(P¼ 0.21). Relative risk for recurrence of MDD calculated with Cox regression
analysis. T , non-T-allele carriers; Tþ , T-allele carriers; TCE , no experience
of TCEs; TCEþ , experienced TCEs.
Table 4 The effects of childhood maltreatment and the MTHFR genotype and
their interaction on depressive symptoms in the replication sample
Sample b s.e. t-Value P-value
Intercept 9.00 2.98 3.02 0.0026**
Gender 1.06 0.50 2.10 0.036*
Age 0.023 0.091 0.26 0.80
Cannabis 1.25 0.56 2.22 0.027*
Childhood
maltreatment
11.08 1.66 6.66 5.7 10 11***
MTHFR genotype 4.13 1.48 2.79 0.0054**
Maltreatment
MTHFR genotype
3.19 1.06 3.03 0.0026**
Abbreviation: MTHFR, methylenetetrahydrofolate reductase.
*Po0.05, **Po0.01, ***Po0.001.
Figure 2 The gene–environment interaction between methylenetetrahydrofo-
late reductase (MTHFR) genotype and traumatic childhood events (TCEs) on
depressive symptoms in 665 individuals from the general population (P¼ 0.0027).
0, T/T genotype; 1, C/T genotype; and 2, C/C genotype.
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cannabis use affected the interaction between childhood
maltreatment and the MTHFR genotype.
In both the discovery and replication samples, no significant
association was found between the genotype and childhood
maltreatment, making the presence of gene–environment
correlations unlikely.
Discussion
This study shows that remitted recurrently depressed patients
with the thermolabile variant of the MTHFR genotype who
have experienced TCEs have a poor prognosis over a follow-
up period of 5.5 years, in terms of recurrence of depression.
This finding supports existing evidence on the specific role of
gene–environment interactions in recurrent depression,
especially when TCEs are examined27 and the overall
reported unfavorable course in patients with childhood
trauma.1 It may explain part of the vulnerability for recurrences
in MDD. In support, we also found a significant interaction
between childhood trauma and the MTHFR genotype on
depressive symptoms in an independent sample from the
general population, underscoring the overall importance of
MTHFR as a genetic risk factor for depression in the context of
early-life stress.
This impact of the combination of early childhood trauma
and C677T MTHFR polymorphism on onset of depressive
symptomatology and recurrences in MDD gives rise to
hypotheses about the underlying pathophysiological path-
ways. The thermolabile variant of the MTHFR gene may
represent a genetic vulnerability factor for limited defense
against (oxidative) stress, because it results in a reduction of
methyl donors for essential methylation processes, for
example, glutathione production and synthesis of neurotrans-
mitters.18 This vulnerability becomes exposed when triggered
by enhanced environmental stress such as childhood
trauma.37 This could be the result of long-lasting trauma-
induced epigenetic changes. These changes include DNA
methylation and chromatin modifications, patterns that are
inherited but responsive to environmental shifts such as
stress, and especially vulnerable during development.58
McGowan et al.59 showed altered methylation of the promoter
region of the glucocorticoid receptor gene in hippocampus
tissue from suicide victims with a history of childhood abuse.
Interestingly, Shalev et al.60 recently reported stress-related
accelerated telomere erosion already in childhood; compared
with their counterparts, children who experienced two or more
kinds of violence exposure showed significantly more
telomere erosion. The authors suggest that these effects
are mediated by oxidative stress. Heim et al.61 proposed that
many of the biological changes thought to be characteristic of
MDD might, in fact, be secondary to early-life trauma and
represent the risk of developing MDD. Moreover, Nanni et al.1
revealed that childhood maltreatment was associated with
lack of response (or remission) during treatment for MDD.
Hypothetically, TCEs disrupt the physiological response to
stress, the overactivation of which may lead to detrimental
consequences in stress-sensitive systems, namely the
nervous, immune, metabolic and endocrine systems.61,62
The resulting cumulative biological ‘weight’ might determine
poor prognosis in terms of recurrences in MDD. However,
thus far, prospective studies in recurrent MDD were lacking.
The observed gene–environment interaction is of
clinical importance, as the burden of MDD is mainly because
of its lifelong recurrent nature.63 The T and TCE patient
groups remained on average recurrence free for 1.85 years
longer than the Tþ and TCEþ patient groups. This suggests
that MDD patients with a childhood trauma history and carriers
of the thermolabile variant of the MTHFR gene constitute a
subgroup of patients who may particularly require tailored
interventions. Those interventions have to combat both MDD
recurrence and the consequences of childhood trauma.1,64,65
The gene–environment interaction in two independent sam-
ples suggests benefit from the integration of two types of
therapeutic approaches: on one hand, psychotherapeutic
interventions specifically aimed at the consequences of TCEs
(including psychotherapeutic treatment of trauma-related
problems) that, on the other hand, could be combined with
interventions aimed at the 1-C cycle; (oxidative) stress may be
corrected by improving antioxidant defenses through dietary
modification and (add-on) exercise.66 These interventions
should be investigated further with randomized controlled
trials in specific high-risk groups.
The limitations of our study include the assessment of TCEs
with a self-report questionnaire rather than an interview.
Those questionnaires may be subject to recall bias through
the effects of depressive symptomatology, and therefore the
validity of such an approach may be reduced.38 However, this
effect may be limited in the discovery sample because at
baseline all participants were euthymic. Moreover, in the
replication sample, all individuals were healthy. Furthermore,
other constructs of TCEs (such as parental neglect, bullying)
than those represented in the used questionnaire could play a
role. In addition, the questionnaire provides no information
regarding the specific timeframe in which the TCEs took place
and how prolonged they were. It could be that the effect of
TCEs is modified by these time-dependent factors. Another
limitation in the discovery sample is the possibility of selection
bias because the final sample contained 124 patients of the
172 patients from the original trial. We lost 8.7% to follow-up
and 19.2% to a diversity of reasons (for example, genotyping
failure, being afraid of needles, ethical issues concerning
genetic study). However, the patients of the final sample did
not differ on the main clinical variables from those excluded
from the analyses. This makes it unlikely that this selection of
124 patients out of the original sample induced any additional
selection bias. Similarly, in the replication sample, we cannot
exclude that recruitment strategies have resulted in a sample
that is not completely representative of the general population
with regard to age and educational level, and therefore we
cannot be sure that the findings in the replication sample can
be generalized to the general population.
In spite of these limitations, our study is unique in providing
the opportunity to investigate the role of the interaction
between genes and environment on prospectively assessed
recurrence over 5.5 years. In addition, this was investigated
in a specific sample of highly recurrent depressed patients,
which can be considered characteristic for those patients
particularly causing the large MDD-associated burden of
disease.63 By including specific recurrently depressed
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patients, we were able to investigate a clinically highly
relevant sample. Our replication of the interaction in a
population sample supports the robustness of our findings
and suggests that this genetic vulnerability is relevant in the
broader context of depression.
In summary, the results of the present study indicate that an
interaction between MTHFR C677T and TCEs increased risk
of recurrence in recurrent MDD patients over 5.5 years of
follow-up and is associated with depressive symptoms in the
general population. More attention to specific at-risk indivi-
duals, that is, patients who experienced TCEs and genetic
alterations, including MTHFR C677T, could help to improve
treatment strategies to prevent depression and recurrences.
However, the exact nature of the connection betweenMTHFR
C677T, TCEs and the course of recurrence in MDD remains to
be clarified. Future, preferably prospective, studies are
warranted to replicate these findings.
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